Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.32 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28499476 | 0.85 | ALDH1A1 (0.32) | KDM4EL3MBTL1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL28823865 | 0.80 | RAPGEF4 (0.38) | KDM4EL3MBTL1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL21388018 | 0.78 | TSHR (0.41) | KDM4EL3MBTL1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL29624394 | 0.78 | TSHR (0.41) | KDM4EL3MBTL1SMN1; SMN2TSHRCASP1 | |
| SCHEMBL3889830 | 0.77 | ALDH1A1 (0.44) | KDM4EL3MBTL1SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL25398474 | 0.75 | ALDH1A1 (0.47) | CASP7ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL21877144 | 0.75 | ALDH1A1 (0.47) | CASP7ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL1218220 | 0.75 | ALDH1A1 (0.47) | CASP7ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL22262524 | 0.75 | ALDH1A1 (0.47) | CASP7ALDH1A1LMNAHPGDMAPT | |
| SCHEMBL8282614 | 0.75 | ALDH1A1 (0.47) | CASP7ALDH1A1LMNAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227366-B2 | Bis-iridium-complexes for manufacturing of ECL-labels | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2673284-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2882764-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| EP-2882823-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2880042-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-9499573-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| EP-2880123-B1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| EP-2880043-B1 | NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS | ROCHE DIAGNOSTICS GMBH (DE) | 2016-09-21 | — | — | EP | disclosed |
| US-9416150-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9403859-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-05-21 | — | — | US | disclosed |
| US-8835637-B2 | Iridium-based complexes for ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| WO-2014019709-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019710-A1 | NEW BIS-IRIDIUM-COMPLEXES FOR MANUFACTURING OF ECL-LABELS | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019708-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019707-A2 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019711-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2014-02-06 | — | — | WO | disclosed |
| EP-2673284-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | Roche Diagnostics GmbH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-20130323719-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2012107419-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ROCHE DIAGNOSTICS GMBH (DE) | 2012-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227366-B2 | Bis-iridium-complexes for manufacturing of ECL-labels | HLCS, PDCD2L, LAS1L | KDM4E 1904/4885L3MBTL1 146/4885SMN1; SMN2 2528/4885 |
| US-20150140682-A1 | IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | KDM4E 4465/4885L3MBTL1 602/4885SMN1; SMN2 4223/4885 |
| US-20130323719-A1 | NEW IRIDIUM-BASED COMPLEXES FOR ECL | ALPL, LIG3, SOD3 | KDM4E 4590/4885L3MBTL1 516/4885SMN1; SMN2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.